Wells Fargo’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
Wells Fargo's GANX Position: Q3 2026 in Review
Wells Fargo reduced its Gain Therapeutics (GANX) stake by 89% in Q3 2026, selling an estimated $15.3K and leaving 1,000 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #6419.
Wells Fargo first reported a position in GANX in Q2 2021 and has held it in 22 quarters since. The position peaked at $21.4K in Q1 2026. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Wells Fargo held 1,000 shares of Gain Therapeutics worth $1.73K as of Q3 2026.
- Wells Fargo sold 8,400 Gain Therapeutics shares in Q3 2026, an estimated $15.3K.
- Gain Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6419 holding.
- Wells Fargo first reported a position in Gain Therapeutics in Q2 2021 and has held it in 22 quarters since.
- Wells Fargo's Gain Therapeutics position peaked at $21.4K in Q1 2026.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.